Co-Diagnostics, Inc. (NASDAQ: CODX) announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., has signed an agreement to expand its commercial and distribution territory across South Asia. The expansion includes Bangladesh, Pakistan, Nepal, and Sri Lanka, increasing the company's addressable market to an estimated $13.0 billion. This move supports the planned commercialization of the CoSara PCR Pro(R) point-of-care platform and SARAGENE(R) product line, subject to regulatory approvals.
The agreement marks a significant milestone for Co-Diagnostics as it builds regional distribution channels and positions for broader deployment of its molecular diagnostics solutions. The expanded territory allows the company to tap into new markets with high demand for affordable and accessible diagnostic tools. The company's technologies, which utilize nucleic acid detection and analysis, are designed for tests that identify genetic markers for infectious diseases and other applications.
Co-Diagnostics develops, manufactures, and markets state-of-the-art diagnostics technologies. Its proprietary technology is used to design specific tests for its Co-Dx PCR at-home and point-of-care platform, which is subject to regulatory review and not currently for sale. The company also identifies genetic markers for use in applications beyond infectious disease.
The expansion comes as part of Co-Diagnostics' strategy to leverage its Indian joint venture to penetrate the South Asian market. CoSara Diagnostics is expected to play a key role in distributing the company's products across the region. The addressable market estimate of $13.0 billion reflects the potential demand for molecular diagnostics in the expanded territory.
For more information about Co-Diagnostics, visit https://co-dx.com/. The full press release is available at https://ibn.fm/2aATV.
